Rekombinanter CD274 (Durvalumab Biosimilar) Antikörper

Produktnummer ABIN7795090

Der Humanized Monoklonal anti-CD274 (Durvalumab Biosimilar) Antikörper (ABIN7795090) detektiert spezifisch CD274 (Durvalumab Biosimilar) in FACS und in vivo. Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für Rekombinanter CD274 (Durvalumab Biosimilar) Antikörper (ABIN7795090)

Target: CD274 (Durvalumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Humanized

Klonalität: Monoklonal

Konjugat: Dieser CD274 (Durvalumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails anti-CD274 (Durvalumab Biosimilar) Antikörper

Expressionssystem: Mammalian cells

Verwendungszweck: Durvalumab Biosimilar, PD-L1 Monoclonal Antibody

Produktmerkmale: Durvalumab Biosimilar uses the same protein sequences as the therapeutic antibody durvalumab. PD-L1 and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD1 (CD279, programmed death 1). Durvalumab is a humanized monoclonal antibody directed against the human protein ligand PD-L1 (B7-H1 or CD274, programmed cell death ligand 1). Durvalumab completely blocks the binding of PDL1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively. Durvalumab is an anticancer antibody that works to promote the antitumor response mediated by immune cells. By blocking the action of PD-L1, durvalumab exerts its anticancer effects by increasing T-cell activation, enhancing detection and ablation of tumor cells. In in vitro assays, durvalumab inhibited the activity of PD-L1 in a concentration-dependent manner. In co-engrafted human tumor and immune cell xenograft mouse models, durvalumab was effective in decreasing tumor size. Durvalumab does not mediate antibody-dependent cell-mediated cytotoxicity (ADCC).

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human PD-L1

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Details zu CD274 (Durvalumab Biosimilar)

Target: CD274 (Durvalumab Biosimilar)

Andere Bezeichnung: Durvalumab Biosimilar

Substanzklasse: Biosimilar